July 16, 2010

FTNW: Diamyd Agreement Approval

Diamyd Agreement Receives Antitrust Clearance
Diamyd Medical AB has received antitrust clearance that closes the transaction announced on June 22, 2010 with Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), a Johnson & Johnson company. 
The US Federal Trade Commission's clearance under the Hart-Scott-Rodino Anti-Trust Improvements Act is regarding the agreement between Diamyd and OMJPI for development and world-wide commercialization of the GAD65 antigen-based therapy (Diamyd®) for the treatment and prevention of type 1 diabetes and associated conditions.  
http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=503738

1 comment:

Bernard Farrell said...

The Diamyd products sounded interesting when I talked with them at CWD. Any idea what Ortho-McNeil are working on?